Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 4 Carcinoma, Non-Small-Cell Lung 4 Lung Neoplasms 3 Melanoma 2 Head and Neck Neoplasms 2 Carcinoma, Hepatocellular 2 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Squamous Intraepithelial Lesions 1 Skin Neoplasms 1 Sarcoma, Synovial 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Recurrence 1 Rectal Neoplasms 1 Prostate Adenocarcinoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Papillomavirus Infections 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neuroblastoma 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Liver Diseases 1 Liposarcoma 1 Laryngeal Neoplasms 1 Hypopharyngeal Neoplasms 1 Breast Neoplasms 1

Interventions

Trastuzumab 597 Paclitaxel 562 Cyclophosphamide 545 Docetaxel 479 Capecitabine 388 Letrozole 350 Fulvestrant 311 Doxorubicin 285 Carboplatin 277 Tamoxifen 257 Anastrozole 219 exemestane 211 Epirubicin 210 Radiotherapy 197 Bevacizumab 189 pertuzumab 177 Gemcitabine 163 Vinorelbine 162 pembrolizumab 161 Lapatinib 161 palbociclib 152 Exercise 132 Fluorouracil 118 Albumin-Bound Paclitaxel 116 eribulin 108 Magnetic Resonance Spectroscopy 108 130-nm albumin-bound paclitaxel 107 Everolimus 103 Taxes 96 Cisplatin 92

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Neoplasms × Adjuvants, Pharmaceutic × Clear all

NCT05296746 2026-05-14

RIBOLARIS

SOLTI Breast Cancer Research Group

Phase 2 Active not recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡